HZA-018 is under clinical development by Hangzhou Hezheng Pharmaceutical and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HZA-018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HZA-018 overview
HZA-018 is under development for the treatment of B cell lymphomas including chronic lymphocytic leukemia, small-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, diffuse large B-cell lymphoma and relapsed or refractory primary or secondary central nervous system lymphoma. The therapeutic candidate is formulated as capsule and administered by oral route. It targets Bruton’s tyrosine kinase (BTK).
For a complete picture of HZA-018’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
